| ID | 10066 |
| Vaccine Name | FAKHRAVAC |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Inactivated |
| Vaccine Status | Approved |
| Manufacturer | Erciyes University, Organization of Defensive Innovation and Research |
| Year of Manufacturing | 2021 |
| Manufacturing Country | Iran |
| Age | 18 - 70 years |
| Dosage | NA |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | SARS-CoV-2 |
| Description | NA |
| Approving Organisation | Iran FDA |
| Collaborating Organisation | Organization of Defensive Innovation and Research |
| Other Countries | NA |
| Trade Name | MIVAC, TURKOVAC |
| PMID | NA |
| Clinical Trial ID | NA |
| Reference Link | https://en.irct.ir/trial/56027 |
| Additional Links | https://www.tehrantimes.com/news/466570/Two-homegrown-vaccines-receive-emergency-use-license
|